Equity in Access Research Grants
Funding Amount
Up to US $2,500,000
Deadline
Deadline not published
Grant Type
Foundation
Overview
The Leukemia & Lymphoma Society's Equity in Access Research Grants aim to enhance equitable access to care for blood cancer patients and survivors. This program funds research to identify effective interventions that increase participation in clinical trials among underrepresented groups. Projects can receive up to $500,000 annually for a maximum of five years, with a total budget cap of $2.5 million. The initiative seeks to address systemic barriers that hinder clinical trial enrollment and improve healthcare access.
The Leukemia & Lymphoma Society’s (LLS) Equity in Access Research Program was created to help ensure more equitable access to care for blood cancer patients and survivors. Through this program, LLS aims to generate new evidence that can guide policy reform and changes in healthcare practice, in order to mitigate the impact of social, economic and environmental disadvantages and reduce barriers to care.
Informed by a systematic review of the literature, the purpose of this Request for Proposals (RFP) is to fund research studies that will increase our understanding of effective interventions for increasing accrual to therapeutic cancer clinical trials, particularly among underrepresented populations. Specifically, we seek proposals that will implement and evaluate interventions designed to a) mitigate multilevel barriers to therapeutic clinical trial accrual for underrepresented groups and b) quantitatively measure the impact of these interventions on patient accrual. We are particularly interested in proposals that address systemic, institutional, and clinician-related barriers that impede clinical trial participation.
Funding Available
Maximum project period is 5 years, and the maximum funding amount per year is $500,000.Total budget, including indirect costs, should not exceed $2.5 million for a 5-year project period.Indirect costs are limited to 11.1% of the total direct costs during the Research Funding Term.
Applicants should request the amount of funding they will need to complete the proposed research and disseminate findings. The review process will include an evaluation of the appropriateness of the funding request in light of study aims and methods to achieve the aims.
What Blood Cancer United Inc actually gave
Source: IRS Form 990, 2025
- Grants in 2025
- 67
- Total given
- $47.75M
- Median grant
- $370K
- Range
- $38K–$5.2M
- By dollars: Massachusetts 17%, New York 16%, California 9%. Top recipient cities: Boston, MA; New York, NY; Philadelphia, PA.
- 0% of grants with a stated purpose were for general or operating support.
- 12% of recipients were new grantees, not repeat recipients.
Example grants
Dana-Farber Cancer Institute Inc · Boston, MA
Research grant
$5.2M
The University of Texas MD Anderson Cancer Center · Houston, TX
Research grant
$2.52M
Sloan Kettering Institute for Cancer Research · New York, NY
Research grant
$2.51M
The Board of Trustees of the Leland Stanford Junior University · Stanford, CA
Research grant
$2.26M
Washington University in St Louis · St Louis, MO
Research grant
$2.25M
Focus Areas & Funding Uses
Fields of Work
- Health disparities
- Science research
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
$6,300,000 total
Deadline
November 9, 2026
Dissemination and Implementation Research in Health (R03 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
January 7, 2028
Community-Based Participatory Research to Advance Data and Practice Transformation (ADAPT) for Optimizing Oral Health for All (UG3/UH3 Clinical Trial Optional)
National Institutes of Health
Amount
Up to $300K
Deadline
November 16, 2028
Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
National Institutes of Health
Amount
$29,000,000 total
Deadline
November 10, 2026
Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
National Institutes of Health
Amount
Varies
Deadline
November 17, 2026
Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
National Institutes of Health
Amount
Varies
Deadline
January 7, 2028
Ready to apply for Equity in Access Research Grants?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Equity in Access Research Grants. Now let's win it.